Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Garrett Motion Q4 2025 Earnings Call - Trane partnership validates e-cooling ramp, industrial cooling to exceed 5% of revenue by 2030
Garrett closed 2025 with solid core performance and a clear strategic pivot into industrial cooling and e-powertrain technologies. Full year net sales were $3.58 billion, adjusted EBIT $510 million (1...
- Q4 2025 net sales were $891 million, adjusted EBIT $122 million, with a 13.7% margin; full year net sales $3.58 billion and adjusted EBIT $510 million, 14.2% margin.
- Adjusted free cash flow for 2025 was $403 million, implying roughly 80% free cash flow conversion for the year.
- Garrett repaid $50 million of its term loan in 2025, repurchased $208 million of common stock (including $72 million in Q4), paid $52 million in dividends, and ended the year with liquidity of $807 million.
- +13 more takeaways
Praxis Precision Medicines Fourth Quarter and Full Year 2025 Earnings Call - Two NDAs Filed, Poised to Transition to a Commercial Company
Praxis closed 2025 with a fast, high-stakes pivot: two NDAs submitted—ulixacaltamide for essential tremor and relutrigine for SCN2A and SCN8A DEEs—while juggling multiple near-term readouts and launch...
- Praxis submitted two NDAs: ulixacaltamide for essential tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).
- Ulixacaltamide received FDA Breakthrough Therapy designation in December after positive Essential3 results that met primary and key secondary endpoints, and the NDA is now filed.
- Relutrigine NDA for SCN2A and SCN8A DEEs has been submitted; the drug has Rare Pediatric Disease Designation and could be eligible for a Pediatric Review Voucher if approved.
- +12 more takeaways
Laureate Education Fourth Quarter and Fiscal Year 2025 Earnings Call - Historic 30.5% Adjusted EBITDA Margin, Net Cash and $150M Buyback Increase
Laureate closed FY2025 with strong top-line growth and margins, reporting $1.702 billion in revenue and a record adjusted EBITDA margin of 30.5% (Adjusted EBITDA $519 million). The company finished th...
- FY2025 revenue $1.702 billion, Adjusted EBITDA $519 million, delivering a record adjusted EBITDA margin of 30.5%.
- Q4 2025: revenue $541 million, Adjusted EBITDA $204 million; reported net income $172 million, GAAP EPS $1.17, adjusted net income $112 million, adjusted EPS $0.76 (up 46% YoY).
- Full-year GAAP net income $284 million, GAAP EPS $1.89; adjusted net income $256 million, adjusted EPS $1.72 (up 22% YoY).
- +16 more takeaways
YETI Holdings Q4 2025 Earnings Call - Tariffs Compress Near-Term Margins, International & Innovation Drive 6%-8% 2026 Sales Guide
YETI closed 2025 with a solid Q4: $583.7 million in revenue, up 5% year-over-year, powered by a 6% lift in Drinkware and a 25% surge in international sales. Management leaned hard into the script they...
- Q4 2025 revenue $583.7 million, +5% year-over-year, YETI’s strongest quarter of the year.
- Drinkware sales $380 million, +6% year-over-year; U.S. drinkware was flat, international demand drove the gain.
- Coolers & Equipment sales $192 million, +2% year-over-year; soft coolers, bags, and cargo performed well despite supply constraints.
- +17 more takeaways
Okeanis Eco Tankers Q4 2025 Earnings Call - Accretive fleet buys meet a structurally tighter crude tanker market led by Venezuelan flows and Sinokor consolidation
Okeanis Eco Tankers closed Q4 2025 riding a freight-cycle tailwind and made opportunistic, accretive moves to expand a modern, in-the-water fleet. Management reported strong quarterly earnings, a cont...
- Q4 fleet-wide time charter equivalent was about $77,000 per vessel per day, with VLCCs at $92,000 and Suezmaxes at $53,100.
- Adjusted EBITDA for Q4 was $79 million, adjusted net profit was $60 million, and adjusted EPS was $1.78 for the quarter.
- Board declared the 15th consecutive quarterly dividend of $1.55 per share, representing 102% of net income on current fully diluted share count; total distributions over the last four quarters were $3.32 per share or roughly 95% of reported net income.
- +17 more takeaways
Alight Q4 2025 Earnings Call - New CEO Prioritizes Execution and AI After $803M Goodwill Hit, Suspends Dividend for Buybacks and Deleveraging
Rohit Verma, 30 working days into the job, framed Alight’s problems as an execution issue not a market one. Q4 and full-year 2025 showed soft renewals, margin pressure and a large non-cash goodwill im...
- New CEO Rohit Verma said Alight’s core issue is execution, not strategy, after 30 working days of client and employee meetings.
- Full-year 2025 revenue was $2.3 billion with adjusted EBITDA of $561 million and adjusted EBITDA margin of ~24.8%, down from $594 million and 25.2% in 2024.
- Q4 2025 revenue was $653 million; recurring revenue $607 million (down 1.6% YoY) and project revenue $46 million (down 27% YoY).
- +12 more takeaways
Madrigal Pharmaceuticals Q4 2025 Earnings Call - Rezdiffra posts near-$1B launch, company pivots to multi-drug MASH franchise
Madrigal closed its first full year of commercial sales with Rezdiffra at $958.4 million and Q4 revenue of $321.1 million, arguing the oral THR-beta agonist has established itself as the foundational ...
- Rezdiffra recorded Q4 2025 net sales of $321.1 million, bringing first full-year commercial sales to $958.4 million, a near-$1 billion launch in year one.
- Madrigal reports more than 36,250 patients on Rezdiffra at the end of Q4, up from over 29,500 at the end of Q3, indicating steady quarter-over-quarter patient adds.
- Management claims Rezdiffra is the foundational therapy in MASH, highlighting an oral, liver-directed profile that prescribers report is performing better than expected in the real world.
- +16 more takeaways
Gold Fields FY2025 Earnings Call - $3bn FCF, record payouts, but Ghana royalty risk looms
Gold Fields closed FY2025 with a cash surge and operational momentum, delivering roughly $3 billion of adjusted free cash flow and 2.44 million attributable ounces, up 18% year on year. Management use...
- Attributable production rose 18% to 2.44 million ounces in FY2025, driven by strong ramp-up at Salares Norte and higher throughput at several Australian assets.
- Adjusted free cash flow was just under $3.0 billion, up 391% year on year, with operations before tax generating about $5.5 billion.
- Headline earnings jumped 170% to $2.6 billion, helped by an average realized gold price near $3,500/oz for the period.
- +12 more takeaways
EPAM Q4 2025 Earnings Call - AI-native revenues scaling, targeting $600M in 2026
EPAM closed 2025 with a strong Q4 beat, driven by a clear strategic shift into AI-native engineering. Q4 revenue was $1.4 billion (up 12.8% reported, 5.6% organic constant currency), with AI-native re...
- Q4 2025 revenue $1.4 billion, up 12.8% year-over-year on a reported basis and +5.6% organic constant currency.
- Full-year 2025 revenue $5.46 billion, +15.4% reported and +4.9% organic constant currency.
- EPAM reported more than $105 million of pure AI-native revenue in Q4 and expects to scale AI-native revenues to in excess of $600 million in 2026.
- +16 more takeaways
Insmed Q4 2025 Earnings Call - BRINSUPRI on track for at least $1B in 2026 after a blockbuster early launch
Insmed spent 2025 turning a clinical win into a commercial one. BRINSUPRI ripped through its first full quarter with $144.6 million in net revenue, prompting management to guide at least $1 billion fo...
- BRINSUPRI posted $144.6 million in net revenue in its first full quarter and management now guides BRINSUPRI revenue of at least $1 billion in 2026.
- Insmed expects total company revenue in 2026 to more than double 2025 levels, driven by BRINSUPRI plus continued ARIKAYCE growth.
- ARIKAYCE had a strong 2025, with Japan producing 40% year-over-year growth and Europe growing faster from a smaller base; ENCORE Phase III readout expected March or April 2026.
- +12 more takeaways